AstraZeneca also acknowledges the NICE recommended provide a AI.

Hologic has been dedicated to to the prevention of cervical cancer through screening since the introduction of the ThinPrep Pap test in 1996. The ThinPrep Pap Test is now the most widely used liquid cytology platform in the United States and many other countries of the world. In 2003, Hologic computer computer – guided imaging system for cervical cancer with the approval of its ThinPrep Imaging System since become the standard of care for the majority of ThinPrep customers implement. With the consent of the Company Cervista HTA system provides Hologic complete cervical solution which is scalable for all laboratory customers.

The Company HPV HR test utilizes Hologic ‘s proprietary Invader technology to 14 high-risk types of HPV associated with cervical cancer and precancerous lesions seen.. All Press Releases,FDA Approves Hologic Cervista High Throughput Automation System for Cervical Cancer ScreeningHologic , a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serve the health care needs of women, today announced that the U.S.AstraZeneca also acknowledges the NICE recommended provide a AI, such as anastrozole, instead of tamoxifen for postmenopausal females with ER-positive EBC, no to low-risk and to 2-3 years for 2-3 years. However, Astra Zeneca want to emphasize that it. No evidence that a scheduled sequencing strategy is a 5-year AI policy for newly diagnosed female having early breast superior.

Related Articles

Other Articles from "specialist":